Technology Development Agency

Technology Development Agency (TDA) is a prominent Russian pharmaceutical development company and the primary R&D arm of the Promomed Group. The company specializes in the rapid development, clinical testing, and registration of high-priority medicines, including antivirals, endocrinology treatments, and biosimilars. TDA achieved international recognition for developing Areplivir (favipiravir), a critical antiviral used in the treatment of COVID-19. Its portfolio also includes advanced treatments for metabolic disorders, such as semaglutide and liraglutide analogs, as well as anticoagulants and oncology supportive care. TDA manages the entire development lifecycle from substance synthesis to multi-center clinical trials, leveraging the manufacturing power of the Biokhimik plant within the Promomed ecosystem. The agency is currently expanding its focus toward innovative biologics and complex small molecules for chronic disease management.